Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): June 9, 2022
Endo International plc
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
of incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
First Floor, Minerva House, Simmonscourt Road
Ballsbridge, Dublin 4,
Not Applicable
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code 011-353-1-268-2000
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Ordinary shares, nominal value $0.0001 per shareENDPThe NASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 9, 2022, Endo International plc (the Company) held its 2022 Annual General Meeting of Shareholders (the Annual Meeting) in Dublin, Ireland. The matters voted on by shareholders at the Annual Meeting and the results of such voting are set forth below.
1.The proposal to elect, by separate resolutions, the following directors, representing all of the members of the Board of Directors of the Company (the Board), to serve until the next annual general meeting of shareholders or until their death, resignation or removal, if earlier, was approved based upon the following votes:
NomineeVotes For ApprovalVotes AgainstAbstentionsBroker Non-Votes
Mark G. Barberio137,600,024 21,517,338 120,869 31,856,803 
Jennifer M. Chao147,997,161 11,122,950 118,120 31,856,803 
Blaise Coleman146,567,870 12,582,189 88,172 31,856,803 
Shane M. Cooke148,102,831 11,044,828 90,572 31,856,803 
Nancy J. Hutson, Ph.D.138,289,425 20,831,038 117,768 31,856,803 
Michael Hyatt103,208,140 55,896,748 133,343 31,856,803 
William P. Montague95,533,427 63,600,281 104,523 31,856,803 
M. Christine Smith, Ph.D.138,566,801 20,544,755 126,675 31,856,803 
2.The proposal to approve, on an advisory basis, the compensation of the Company's named executive officers received the following votes:
Votes for approval24,395,060 
Votes against134,650,506 
Broker non-votes31,856,803 
3.The proposal to renew the Board's existing authority to issue shares under Irish law was approved based upon the following votes:
Votes for approval170,131,044 
Votes against20,522,869 
4.The proposal to renew the Board's existing authority to opt-out of statutory pre-emption rights under Irish law was approved based upon the following votes:
Votes for approval170,652,158 
Votes against19,971,371 
5.The proposal to approve the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2022 and to authorize the Board, acting through the Audit & Finance Committee, to determine the independent registered public accounting firm's remuneration was approved based upon the following votes:
Votes for approval172,674,579 
Votes against1,556,953 
6.Such other matters as may properly come before the Annual Meeting or any adjournment or postponement thereof:

Item 9.01. Financial Statements and Exhibits.
(d)    Exhibits.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
By:/s/ Matthew J. Maletta
Name:Matthew J. Maletta
Title:Executive Vice President,
Chief Legal Officer and Company Secretary
Dated: June 9, 2022